摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-methoxy-N-methyl-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazole-2-carboxamide | 799781-97-8

中文名称
——
中文别名
——
英文名称
N-methoxy-N-methyl-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazole-2-carboxamide
英文别名
N-methoxy-N-methyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carboxamide
N-methoxy-N-methyl-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazole-2-carboxamide化学式
CAS
799781-97-8
化学式
C9H13N3O2
mdl
——
分子量
195.221
InChiKey
FWHHOSCDELSADD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    47.4
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-methoxy-N-methyl-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazole-2-carboxamide 在 lithium aluminium tetrahydride 作用下, 以 四氢呋喃 为溶剂, 反应 10.0h, 以67%的产率得到5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carbaldehyde
    参考文献:
    名称:
    Process for synthesizing beta-lactamase inhibitor intermediates
    摘要:
    提供了一种制备具有结构式I的双环杂环芳基羰基的方法,其中X和Y在规范中定义。这些双环杂环芳基羰基在β-内酰胺酶抑制剂的制备中作为中间体是有用的。
    公开号:
    US20040242874A1
  • 作为产物:
    描述:
    potassium 5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazole-2-carboxylate 在 氯化亚砜potassium carbonate 作用下, 以 二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 3.5h, 生成 N-methoxy-N-methyl-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazole-2-carboxamide
    参考文献:
    名称:
    Selective Hydrolysis of Ethyl 5,6-Dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carboxylate and Ethyl 5,6-Dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylate as a Key Step in the Large-Scale Synthesis of Bicyclic Heteroaryl Carboxyaldehydes
    摘要:
    The isomeric mixture of ethyl 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2- and -3-carboxylates ( 14 and 15), derived from a proline meso-ionic synthon, demonstrated remarkably different stabilities towards alkaline hydrolysis. On that basis, a non-chromatographic, highly efficient method for their large-scale separation was developed. The desired isomer 14 was converted into 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carbaldehyde, a key intermediate in the synthesis of bicyclic heteroaryl-substituted 6-alkylidene penems.
    DOI:
    10.1021/op050218b
点击查看最新优质反应信息

文献信息

  • Production of bicyclic-heteroaryl-2-carboxylic acids by selective enzymatic hydrolysis of a mixture of positional esters
    申请人:Wyeth Holdings Corporation
    公开号:US20040229324A1
    公开(公告)日:2004-11-18
    The invention relates to an enzymatic process for the production of an intermediate, bicyclic-heteroaryl-2-carboxylic acid, of the formula 1 wherein X and Y are defined in the specification and which are useful in the preparation of beta-lactamase inhibitors, by selective enzymatic hydrolysis of a mixture of positional hydrolyzable esters of the formulae 2 where X, Y, and R are defined in the specification.
    本发明涉及一种酶法生产中间体双环杂芳基-2-羧酸的方法,其化学式为1,其中X和Y在规范中定义,并且在β-内酰胺酶抑制剂的制备中有用,通过选择性酶解式2的可位解酯混合物来实现,其中X、Y和R在规范中定义。
  • PROCESS FOR SYNTHESIZING ß-LACTAMASE INHIBITOR INTERMEDIATES
    申请人:Wyeth Holdings Corporation
    公开号:EP1626972A1
    公开(公告)日:2006-02-22
  • US7276611B2
    申请人:——
    公开号:US7276611B2
    公开(公告)日:2007-10-02
  • US7316917B2
    申请人:——
    公开号:US7316917B2
    公开(公告)日:2008-01-08
  • [EN] PROCESS FOR SYNTHESIZING beta-LACTAMASE INHIBITOR INTERMEDIATES<br/>[FR] PROCESSUS DE SYNTHESE D'INTERMEDIAIRES DE L'INHIBITEUR DE 20041202WO03093277A1WYETH CORP [US], et al20031113Claims 1-16; p. 5, l. 32-p. 7, l. 3; example 21PX1-63PXEP1241170A2PFIZER LTD [GB], et al20020918p. 29, route A, step iv); preparations 28-29X1-63,1-19,60A20-59,61-63XAJ.N. LEE ET AL.: "Synthesis of New Pyrazolylisoxazolines via 1,3-Dipolar Cycloaddition Reaction of Bicyclic Sydnone with Benzyl Propiolate", BULL. KORENA CHEM. SOC., vol. 21, no. 8, 2000, pages 761 - 762, XP002300479J.N. LEE ET AL.Synthesis of New Pyrazolylisoxazolines via 1,3-Dipolar Cycloaddition Reaction of Bicyclic Sydnone with Benzyl PropiolateBULL. KORENA CHEM. SOC.2000218761762Scheme 1, steps 1) to 4)X1-63,1-19,60A20-59,61-63XAWO9410178A1SMITHKLINE BEECHAM PLC [GB], et al19940511Claim 13; preparations 1-5; p. 8, l. 17-p. 13, l. 2A1-63AEP0084892A2SUMITOMO CHEMICAL CO [JP]19830803Claim 1p. 2, l. 8-p. 5, last lineA1-63ASCHMID A ET AL: "INDUSTRIAL BIOCATALYSIS TODAY AND TOMORROW", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 409, 11 January 2001 (2001-01-11), pages 258 - 268, XP000985347, ISSN: 0028-0836SCHMID A ET ALINDUSTRIAL BIOCATALYSIS TODAY AND TOMORROWNATURE, MACMILLAN JOURNALS LTD. LONDON, GB200101114090028-0836258268Fig. 2 and 4A1-63AB.G. DAVIS; V. BOYER: "Biocatalysis and enzymes in organic synthesis", NAT. PROD. REP., vol. 18, 2001, pages 618 - 640, XP002300480B.G. DAVIS; V. BOYERBiocatalysis and enzymes in organic synthesisNAT. PROD. REP.200118618640Point 2.1, Table 1; Point 2.2, schemes 9-10 and 15, Table 3A1-63A
    申请人:WYETH CORP
    公开号:WO2004104008A1
    公开(公告)日:2004-12-02
    The invention relates to an enzymatic process for the production of an intermediate, bicyclic-heteroaryl-2-carboxylic acid, of the formula (I) wherein X and Y are defined in the specification and which are useful in the preparation of beta-lactamase inhibitors, by selective enzymatic hydrolysis of a mixture of positional hydrolyzable esters of the formula (II) and (III) where X, Y and R are defined in the specification.
查看更多

同类化合物

奥格列汀 吡唑并[3,4-a]吡咯里嗪 叔丁基3'-氨基-1',4'-二氢-5'H-螺[环丁烷-1,6'-吡咯并[3,4-C]吡唑]-5'-羧酸酯 5-苄基-1,4,5,6-四氢吡咯并[3,4-c]吡唑-3-羧酸乙酯 5-甲基-1H,4H,5H,6H-吡咯并[3,4-C]吡唑 5-叔丁基3-乙基4,6-二氢吡咯并[3,4-c]吡唑-3,5(1h)-二羧酸 5-叔丁基1-乙基3-氨基-3A,4,6,6A-四氢吡咯并[3,4-C]吡唑-1,5-二甲酯 5-BOC-3-氨基-4,6-二氢吡咯并[3,4-C]吡唑-1-甲酸乙酯 5,6-二氢-4H-吡咯并[1,2-b]吡唑-2-羧酸乙酯 5,6-二氢-4H-吡咯并[1,2-b]吡唑 5,6-二氢-4H-吡咯并[1,2-B]吡唑-3-羧酸 5,6-二氢-4H-吡咯并[1,2-B]吡唑-3-甲醛 5,6-二氢-4H-吡咯并[1,2-B]吡唑-2-羧酸 5,6-二氢-3-羟基-4H-吡咯并[1,2-c][1,2,3]恶二唑-7-鎓内盐 4a,6c-二氮杂环丁[a]环戊二烯并[Cd]并环戊二烯 4,6-二氢吡咯并[3,4-C]吡唑-3,5(1H)-二甲酸5-叔丁酯 4,6-二氢-1H-吡咯[3,4-C]吡唑-5-甲酸丁酯 3-甲基-1H,4H,5H,6H叔丁基吡咯并[3,4-c]吡唑-5-羧酸酯 3-甲基-1,4,5,6-四氢-吡咯并[3,4-c]吡唑 3-溴-5,6-二氢-4H-吡咯并[1,2-b]吡唑 3-氨基-6-乙基-4,6-二氢吡咯并[3,4-C]吡唑-5(1H)-羧酸叔丁酯 3-氨基-6,6-二甲基-4,6-二氢吡咯并[3,4-C]吡唑-5(2H)-羧酸叔丁酯 3-氨基-6,6-二甲基- 吡咯并[3,4-c]吡唑-2,5(4H,6H)-二羧酸 5-(1,1-二甲基乙基) 2-乙酯 3-氨基-5-叔丁氧羰基-吡咯并[3,4-C]吡唑 3-氨基-4,6-二氢吡咯并[3,4-C]吡唑-5-甲酸叔丁酯 3-氨基-4,6-二氢-6,6-二甲基-吡咯并[3,4-c]吡唑-1,5-二甲酸 5-叔丁基 1-乙基酯 3-(4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷-2-基)-5,6-二氢-4H-吡咯并(1,2-B)吡唑 2-甲基-2-丙基3'-氨基-1',4'-二氢-5'H-螺[环丙烷-1,6'-吡咯并[3,4-c]吡唑]-5'-羧酸酯 2-甲基-2,4,5,6-四氢吡咯并[3,4-C]吡唑二盐酸盐 2-(甲基磺酰基)-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-羧酸叔丁酯 2,4,5,6-四氢-2-(甲基磺酰基)-吡咯并[3,4-c]吡唑 2,3-二氮杂三环[5.2.1.02,6]癸-1(9),3,5,7-四烯 1-甲基-1,4,5,6-四氢吡咯并[3,4-c]吡唑盐酸盐 1-(4-四氢吡喃基)-1,4,5,6-四氢吡咯并[3,4-C]吡唑盐酸盐 1-(3-氨基-4,5-二氢-1H-吡唑-1-基)-1-丙酮 1-(3-氨基-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-基)乙酮 1,4,5,6-四氢吡咯并[3,4-c]吡唑-3-胺 1,4,5,6-四氢吡咯并[3,4-C]吡唑 1,4,5,6-四氢吡咯并-[3,4-c]-吡唑双盐酸盐 1,4,5,6-四氢-1-甲基吡咯并[3,4-C]吡唑 (S)-3-氨基-N-(2-(二甲基氨基)-1-苯基乙基)-6,6-二甲基-4,6-二氢吡咯并[3 (9CI)-2,4,5,6-四氢-2-甲基-吡咯并[3,4-c]吡唑 2-(1-imidazolylcarbonylamino)-6-[2(R),6-dimethylheptyl]-4[1H]-pyrimidinone ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-(1-(trifluoromethyl)cyclopropanecarboxamido)-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate 3-[(cyclobutylcarbonyl)amino]-N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carboxamide ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-(1-(trifluoromethyl)cyclobutanecarboxamido)-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate 4-Methoxy-6,7-dimethyl-3,4-dihydro-pteridine; hydrochloride 5-(3-chloro-2-fluoro-phenyl)-4-(4-chloro-2-methyl-phenyl)-3-isopropyl-2-(2-methyl-thiazol-4-ylmethyl)-4,5-dihydro-2H-pyrrolo[3,4-c]pyrazol-6-one 4-(4-chloro-2-methyl-phenyl)-5-(5-chloro-2-methyl-phenyl)-3-isopropyl-2-(4-methyl-piperazine-1-carbonyl)-4,5-dihydro-2H-pyrrolo[3,4-c]pyrazol-6-one 4-(4-chloro-2-methyl-phenyl)-5-(5-chloro-2-methyl-phenyl)-2-(2,3-dihydroxy-propyl)-3-isopropyl-4,5-dihydro-2H-pyrrolo[3,4-c]pyrazol-6-one